- Medtronic’s adjusted earnings per share (EPS) for Q3 were $1.39, up from $1.30 year-over-year, surpassing the estimate of $1.36.
- Total revenue reached $8.29 billion, a 2.5% increase from last year, but slightly below the estimate of $8.33 billion.
- Cardiovascular revenue matched expectations at $3.04 billion, representing a 3.7% increase from the previous year.
- Medical Surgical revenue fell by 3.5% to $2.07 billion, missing the estimated $2.14 billion.
- Neuroscience revenue rose by 4.4% to $2.46 billion, slightly above the estimate of $2.45 billion.
- Revenue from the Diabetes segment increased by 8.4% to $694 million, exceeding the estimate of $680.7 million.
- The adjusted gross margin improved to 66.6% from 66.1% year-over-year, outperforming the estimate of 65.6%.
- The adjusted operating margin rose to 26.2%, up from 25.2% year-over-year, and above the estimated 25.6%.
- Medtronic reiterated its full-year revenue and EPS guidance, expecting FY25 organic revenue growth between 4.75% to 5%.
- The company forecasts FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
- Medtronic anticipates accelerating growth in Q4, aiming for high-single digit adjusted EPS growth in the later half of the fiscal year.
- Analyst ratings include 15 buys, 16 holds, and 2 sells.
Medtronic Plc on Smartkarma
Analysts on Smartkarma, like Baptista Research, are closely following Medtronic Plc and recent developments. Baptista Research, in their report titled “Medtronic plc: Are Its Investments in Robotics with Hugo Robotic-Assisted Surgery System Yielding Results? – Major Drivers,” highlighted the positive trajectory of Medtronic PLC’s fiscal 2025 first-quarter results. The report noted that key financial metrics met or exceeded expectations, with revenue growth reaching 5.3% driven by strong performances in Cardiovascular, Neuroscience, and Diabetes segments. The earnings call also emphasized continued growth and strategic advancements in product innovations and global market expansions.
A look at Medtronic Plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc, a company that develops therapeutic and diagnostic medical products, has been assigned Smartkarma Smart Scores indicating its overall outlook. With a Value score of 3, Growth score of 3, Resilience score of 3, Dividend score of 4, and Momentum score of 4, Medtronic appears to have a positive long-term outlook. The company’s solid Dividend and Momentum scores suggest stability and positive investor sentiment, while the Growth and Resilience scores indicate potential for steady expansion and resilience in the face of challenges. Although the Value score is moderate, the overall picture for Medtronic on Smartkarma Smart Scores seems promising.
Medtronic Plc has a wide range of medical products that are essential for various health conditions worldwide. Their products cover areas such as bradycardia pacing, heart valve replacement, pain management, and movement disorders. With an emphasis on innovation and global reach, Medtronic is positioned to continue its trajectory of growth and stability in the medical industry. Investors may find Medtronic appealing due to its strong Dividend and Momentum scores, alongside the company’s focus on developing cutting-edge solutions for critical medical needs.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
